This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 25
-Paragraph 23
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479405/805-10-25-23

Licenses and Collaborations - Additional Information (Detail) - USD ($) $ in Thousands		1 Months Ended		3 Months Ended		9 Months Ended			12 Months Ended
	Oct. 31, 2020	May 31, 2021	Dec. 31, 2020	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2021
License and Collaborations [Line Items]
Research and development				$ 40,314	$ 16,100	$ 92,825	$ 57,440
Ares Trading S A [Member]
License and Collaborations [Line Items]
Aggregate annual sales1			$ 250,000
Aggregate annual sales net2			500,000
Ares Trading S A [Member] \| Achievement Of Specified BLA Filing Or Regulatory Approval Milestones [Member]
License and Collaborations [Line Items]
Milestone payments payable			15,000
Ares Trading S A [Member] \| Aggregate Annual Net Sales Reach $250 Million [Member]
License and Collaborations [Line Items]
Milestone payable on aggregate annual sales1			15,000
Ares Trading S A [Member] \| Aggregate Annual Net Sales Reach $500 Million [Member]
License and Collaborations [Line Items]
Milestone payable on aggregate annual sales2			50,000
Ares Agreement [Member] \| Ares Trading S A [Member]
License and Collaborations [Line Items]
Milestone payments payable			25,000
Related party transaction, expenses from transactions with related party				100	$ 400	300	$ 2,400
Ares Agreement [Member] \| Ares Trading S A [Member] \| Achievement Of Specified BLA Filing Or Regulatory Approval Milestones [Member]
License and Collaborations [Line Items]
Milestone payments payable			176,500
Ares Agreement [Member] \| Ares Trading S A [Member] \| Achievement Of Specified Commercial Milestones [Member]
License and Collaborations [Line Items]
Milestone payments payable			515,000
Ares Agreement [Member] \| Ares Trading S A [Member] \| Regulatory Approval In The U.S [Member]
License and Collaborations [Line Items]
Milestone payments payable			$ 20,000
Amplyx Agreement [Member]
License and Collaborations [Line Items]
Milestone payments payable									$ 2,000
Acquisition cost									5,000
Research and development									7,000
Reduction in contingent future development								$ 7,000
Contingent milestone obligation accrued									$ 2,000
Company shares issued								$ 5,700
Amplyx Agreement [Member] \| Amplyx and Novartis [Member] \| Achievement of Various Clinical Development and Regulatory Milestones [Member]
License and Collaborations [Line Items]
Milestone payments payable				7,000		7,000
Novartis [Member] \| Amplyx and Novartis [Member] \| Achievement of Various Clinical Development and Regulatory Milestones [Member]
License and Collaborations [Line Items]
Milestone payments payable				$ 62,000		$ 62,000
Series C [Member] \| Ares Agreement [Member] \| Ares Trading S A [Member]
License and Collaborations [Line Items]
Temporary equity stock shares issued during the period shares		1,913,501
Temporary equity shares issued during the period value	$ 13,100
Common Class A [Member]
License and Collaborations [Line Items]
Company shares issued								283,034